Financhill
Back

Mirati Therapeutics Quote, Financials, Valuation and Earnings

Mirati Therapeutics Price Quote

$39.07
-0.03 (0.77%)
(Updated: March 25, 2023 at 5:21 AM ET)

Mirati Therapeutics Key Stats

Sell
13
Mirati Therapeutics (MRTX) is a Sell

Day range:
$36.92 - $39.19
52-week range:
$32.96 - $101.30
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
176.80
P/B ratio:
2.28%

Volume:
1.1M
Avg. volume:
1M
1-year change:
-52.42%
Market cap:
$2.3B
Revenue:
$12.4M
EPS:
$-13.18

How Much Does Mirati Therapeutics Make?

Is Mirati Therapeutics Growing As A Company?

  • What Is Mirati Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 2.12%
  • What Is Mirati Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Mirati Therapeutics Stock Price Performance

What Is Mirati Therapeutics 52-Week High & Low?

Mirati Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Mirati Therapeutics?

Is Mirati Therapeutics Cash Flow Positive?

  • What Is MRTX Cash Flow From Operations?
    Cash flow from operations (TTM) is -$570.6M
  • What Is Mirati Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $166.9M
  • What Is Mirati Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $225.8M

Mirati Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    MRTX return on invested capital is -63.03%
  • What Is Mirati Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -54.58%
  • What Is MRTX Return On Equity?
    ROE is a measure of profitability and is -63.03%

Mirati Therapeutics Earnings Date & Stock Price

Mirati Therapeutics Competitors

  • Who Are Mirati Therapeutics's Competitors?
    Below is a list of companies who compete with Mirati Therapeutics or are related in some way:
    • Bristol-Myers Squibb Co (BMY)
    • iBio Inc (IBIO)
    • NovaBay Pharmaceuticals Inc (NBY)
    • Palatin Technologies Inc (PTN)
    • Theriva Biologics Inc (TOVX)

Mirati Therapeutics Dividend Yield

Data Unavailable

Mirati Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 2.55%
Revenue: 212.38% -64.77%

Analyst Recommendations

Buy Recommendations: 5
Hold Recommendations: 8
Sell Recommendations: 0
Price Target: 70.73
Upside from Last Price: 80.9%

Major Shareholders

  • How many MRTX shares are owned by institutional investors?
    83.6M MRTX shares are owned by institutional investors
  • How many MRTX shares are owned by insiders?
    983.6K MRTX shares are owned by insiders